Quanta Dialysis Technologies (Alcester, U.K.) said today that it has closed on a £38 million ($48 million) Series C funding round.
The money will support the British commercial launch of the company’s SC+ personal hemodialysis system as well as a 510(k) clearance submission to U.S. FDA later this year.
The SC+, which received a CE Mark in the E.U. in 2015, includes a design innovation that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. Users dispose of the cartridge after every treatment, and a touch-screen interface is meant to improve ease of use.
The goal is to enable a wider range of users, including the actual people suffering from kidney problems, to manage dialysis therapy — not only in an outpatient clinic but also at home.
A Swiss private family office led the Series C round in combination with Btov Partners and co-led by Wellington Partners and Seroba Life Sciences, along with participation from other existing investors.
There are millions of people around the world who need dialysis, with little innovation over the years, according to Christian Schütz, managing director of Btov Partners, on behalf of the lead investors.
“We are confident that SC+ will provide a much-needed solution to help health systems deliver better value for money whilst at the same time improving patients’ lives,” Schütz said in a news release.
